Protective effects of estradiol in the brain of rats with genetic or mineralocorticoid-induced hypertension.
Abnormalities of hippocampus and hypothalamus are commonly observed in rats with genetic (SHR) or mineralocorticoid/salt-induced hypertension. In the hippocampus, changes include decreased cell proliferation in the dentate gyrus (DG), astrogliosis and decreased neuronal density in the hilus, whereas in the hypothalamus expression of arginine vasopressin (AVP) is markedly elevated. Here, we report that estradiol treatment overturns these abnormalities. We used 16-week-old male SHR with blood pressure (BP) approximately 190 mmHg and their normotensive Wistar-Kyoto (WKY) controls, and male Sprague-Dawley rats made hypertensive by administration of 10mg deoxycorticosterone acetate (DOCA) every other day plus 1% NaCl as drinking fluid for 4 weeks (BP approximately 160 mmHg). Controls received oil vehicle plus 1% NaCl only. Half of the animals in each group were implanted s.c. with a single estradiol benzoate pellet weighing 14 mg for 2 weeks. Estradiol-treated SHR and DOCA-salt rats showed, in comparison to their respective steroid-free groups: (a) enhanced proliferation in the DG measured by bromodeoxyuridine incorporation; (b) decreased number of glial fibrillary acidic protein (GFAP) immunopositive astrocytes; (c) increased density of neurons in the hilus of the DG, and (d) decreased hypothalamic AVP mRNA expression. These results indicate that neuronal and glial alterations of hypertensive models are plastic events reversible by steroid treatment. The estradiol protective effects may be of pharmacological interest to attenuate the consequences of hypertensive encephalopathy.
Pietranera
Luciana
L
Laboratory of Neuroendocrine Biochemistry, Instituto de Biologia y Medicina Experimental, Buenos Aires, Argentina.
Saravia
Flavia E
FE
Roig
Paulina
P
Lima
Analia
A
De Nicola
Alejandro F
AF
D000818:Animals; D001127:Arginine Vasopressin / Q000096:biosynthesis; D001921:Brain / Q000473:pathology*; D001973:Bromodeoxyuridine / Q000494:pharmacology; D049109:Cell Proliferation / Q000187:drug effects; D018891:Dentate Gyrus / Q000473:pathology; D003900:Desoxycorticosterone; D004958:Estradiol / Q000494:pharmacology*; D005904:Glial Fibrillary Acidic Protein / Q000378:metabolism; D006973:Hypertension / Q000139:chemically induced / Q000235:genetics / Q000473:pathology*; D007150:Immunohistochemistry; D017403:In Situ Hybridization; D008297:Male; D008901:Mineralocorticoids; D009474:Neurons / Q000473:pathology / Q000648:ultrastructure; D018696:Neuroprotective Agents; D012333:RNA, Messenger / Q000096:biosynthesis / Q000235:genetics; D051381:Rats; D011918:Rats, Inbred SHR; D011921:Rats, Inbred WKY; D017207:Rats, Sprague-Dawley
D005904:Glial Fibrillary Acidic Protein; D008901:Mineralocorticoids; D018696:Neuroprotective Agents; D012333:RNA, Messenger; D001127:Arginine Vasopressin; D003900:Desoxycorticosterone; D004958:Estradiol; D001973:Bromodeoxyuridine